Jürgen Kübler is a seasoned professional with over 30 years of experience in drug safety and pharmacovigilance. Currently serving as the Co-Chair of the ASA Biopharm Safety Working Group, Jürgen is dedicated to advancing the field of drug safety through collaboration, innovation, and best practices. With a strong background in quantitative sciences, he brings a unique perspective to the table, combining scientific expertise with a keen understanding of the complex regulatory landscape.
Throughout his career, Jürgen has demonstrated a commitment to ensuring the safety and well-being of patients by proactively identifying and mitigating potential risks associated with pharmaceutical products. His strategic approach to pharmacovigilance has not only helped companies navigate regulatory requirements more effectively but has also contributed to the development of safer and more effective medications.
As a thought leader in the field, Jürgen is passionate about sharing his knowledge and insights with the broader drug safety community. He is a frequent speaker at industry conferences and events, where he addresses key challenges facing safety professionals and offers practical solutions to enhance pharmacovigilance practices. Jürgen's collaborative and results-driven approach has earned him a reputation as a trusted advisor and mentor to colleagues and peers alike.
At the World Drug Safety Congress Europe 2025, Jürgen Kübler will bring his expertise to the forefront, engaging with fellow safety professionals to discuss and tackle the most pressing issues in drug safety today. His participation in this prestigious event underscores his dedication to driving continuous improvement in drug safety practices and his commitment to advancing patient care through excellence in pharmacovigilance.